trending Market Intelligence /marketintelligence/en/news-insights/trending/v4fN3DH9rDVjtJ4vrCHl-A2 content esgSubNav
In This List

Aradigm respiratory disease drug not likely to get EMA backing

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


Aradigm respiratory disease drug not likely to get EMA backing

Aradigm Corp. said its respiratory disease drug Linhaliq is not likely to get the backing of the European Medicines Agency in November.

The Hayward, Calif.-based company previously filed a centralized marketing authorization application for Linhaliq for treating non-cystic fibrosis bronchiectasis patients with chronic lung infections with P. aeruginosa. Non‐cystic fibrosis bronchiectasis is a condition in which the bronchial tubes in the lungs are scarred and widened.

Aradigm said it received feedback, following an oral explanation with the EU agency, that the drug is likely to receive a negative opinion from the EMA's Committee for Medicinal Products for Human Use.

Amsterdam-based EMA makes recommendations to the European Commission, which ultimately decides whether to approve or reject manufacturers' applications for marketing approval in the European Union.

Meanwhile, the company is also seeking approval in the U.S. for the drug, known in the U.S. as Apulmiq, for the same indication. In January, the company completed an independent third-party evaluation of two phase 3 studies for the therapy as requested by the U.S. Food and Drug Administration.

In February, Aradigm filed for bankruptcy protection and said it intends to begin selling substantially all of its assets.